US 9629899
Targeted cargo protein combination therapy
granted A61KA61K31/513A61K31/519
Quick answer
US patent 9629899 (Targeted cargo protein combination therapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/513, A61K31/519, A61K31/555, A61K31/704